Lapatinib Ditosylate from Japan
Lapatinib ditosylate is a dual tyrosine kinase inhibitor for HER2-positive breast cancer. The core quinazoline structure (aromatic heterocyclic with nitrogen) places it under HTS 2933.99.75.00 as a drug.
Duty Rate — Japan → United States
12.5%
Rate breakdown
9903.05.4912.5%Section 301 (forced labor) — Japan (col1 rate < 12.5 percent): MFN < 12.5% → total duty capped at 12.5%
Import Tips
• Declare as 'Lapatinib ditosylate monohydrate' if hydrated form per CoA
• Include bioequivalence data if generic import competing with originator